Stryker completes US $4.9 billion acquisition of Inari Medical

USA – Stryker has finalized its US $4.9 billion acquisition of Inari Medical, strengthening its position in the peripheral vascular market.

The deal, announced last month, brings Inari’s innovative venous thromboembolism (VTE) treatment solutions under Stryker’s expanding endovascular portfolio.

Inari specializes in mechanical thrombectomy devices that remove blood clots without using thrombolytic drugs.

Its FlowTriever system treats pulmonary embolism (PE), while the ClotTriever system is designed for deep vein thrombosis (DVT).

These solutions align with Stryker’s Neurovascular business, helping the company expand in the fast-growing VTE treatment segment.

Stryker Chair and CEO Kevin Lobo highlighted the deal’s importance, stating, “The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio. We look forward to working together to improve patient outcomes worldwide.”

Beyond its core thrombectomy solutions, Inari’s portfolio includes the LimFlow system, a device for treating chronic limb-threatening ischemia, and the Artix thrombectomy system for acute limb ischemia.

These additions enhance Stryker’s ability to offer advanced solutions for vascular conditions.

Financial and market impact

With the acquisition complete, Inari is now a wholly-owned subsidiary of Stryker. Trading of Inari’s shares ceased on February 19, 2025, and the company was delisted from the Nasdaq Global Select Market.

Under the agreement, Stryker acquired all outstanding shares of Inari common stock for US $80 per share.

This deal follows Stryker’s acquisition of NICO Corp. in September 2024, a company specializing in minimally invasive brain surgery technologies.